MWNA
ITOS

Marshall Wace North America’s iTeos Therapeutics ITOS Stock Holding History

Marshall Wace North America’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$863K Sell
31,976
-179,119
-85% -$4.68M ﹤0.01% 976
2021
Q2 		$5.42M Buy
+211,095
New +$5.03M 0.02% 529

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Marshall Wace North America's ITOS Position: Q3 2021 in Review

Marshall Wace North America reduced its iTeos Therapeutics (ITOS) stake by 85% in Q3 2021, selling an estimated $4.68M and leaving 31,976 shares worth $863K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Marshall Wace North America first reported a position in ITOS in Q2 2021 and has held it in 2 quarters since. The position peaked at $5.42M in Q2 2021. 77 funds tracked by Wall St. Rank hold ITOS as of Q3 2021.

  • Marshall Wace North America held 31,976 shares of iTeos Therapeutics worth $863K as of Q3 2021.
  • Marshall Wace North America sold 179,119 iTeos Therapeutics shares in Q3 2021, an estimated $4.68M.
  • iTeos Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #976 holding.
  • Marshall Wace North America first reported a position in iTeos Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • Marshall Wace North America's iTeos Therapeutics position peaked at $5.42M in Q2 2021.
  • 77 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.